Ramos

Burkitt's lymphoma, B lymphocyte

Cell Type:
B cell
Tissue Origin:
Species:
human
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:
Suspension

Recommended Media

RPMI-1640 medium was developed by Moore et al., at Roswell Park Memorial Institute, hence the acronym RPMI. The formulation is based on the RPMI-1630 series of media utilizing a bicarbonate buffering system and alterations in the amounts of amino acids and vitamins. RPMI-1640 medium has been used for the culture of human normal and neoplastic leukocytes. RPMI-1640 when properly supplemented, has demonstrated wide applicability for supporting growth of many types of cell cultures, including fresh human lymphocytes in the 72-hour phytohemagglutinin (PHA) stimulation assay.

There are a variety of formulations:
12-702         - with L-glutamine
BE12-702/U1 - with UltraGlutamineI
BE15-702D    - [powder] with L-glutamine
12-167          - without L-glutamine
12-115          - with L-glutamine and 25 mM HEPES buffer
BE12-115/U1 - with UltraGlutamineI and 25 mM HEPES buffer
04-525          - with L-glutamine and 165 nM MOPS (used for some mycological assays)
09-774          - with L-glutamine, 25 mM HEPES buffer 100 units/ml penicillin, 50 ug/ml streptomycin
12-918          - without L-glutamine or phenol red
BE12-752       - with L-glutamine, without D-glucose

Storage = 2ºC to 8ºC 
  (versions without L-glutamine and those with UltraGlutamine can be stored at 15ºC to 30ºC)

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
SG CA-137 2e6 51% 75-79% Plasmid (general) 2 µg 100 µl 4D X-Unit
SG CA-137 4e5 39-41% 69-71% Plasmid (general) 400 ng 20 µl 4D X-Unit
V O-006 2e6 20-34% 67-77% Plasmid (general) 2 µg 100 µl I/II/2b
SG CA-137 5e5 20-30% 70-86% siRNA 20 µl Shuttle
SG CM-138 5e5 20-30% 70-86% siRNA 20 µl Shuttle

Citations

Categories:
Transfection 
Authors:
Ingle GS, Chan P, Elliott JM, Chang WS, Koeppen H, Stephan JP, Scales SJ 
In:
Br J of Haematol (2008) 140(1): 46-58 
Categories:
Transfection 
Authors:
Sundberg TB, Ney GM, Subramanian C, Opipari AW Jr and Glick GD 
In:
Cancer Res (2006) 66(3): 1775-1782 
Categories:
Transfection 
Authors:
Kim YJ, Sekiya F, Poulin B, Bae YS and Rhee SG 
In:
Mol Cell Biol (2004) 24(22): 9986-9999 
Categories:
Transfection 
Authors:
Jiang XZ, Toyota H, Yoshimoto T, Takada E, Asakura H, Mizuguchi J 
In:
Apoptosis (2003) 8(5): 509-19